Lexeo Therapeutics (NASDAQ:LXEO) COO Jose Manuel Otero Sells 4,666 Shares

Posted by Geri Gentry on Jul 2nd, 2026

Lexeo Therapeutics, Inc. (NASDAQ:LXEO – Get Free Report) COO Jose Manuel Otero sold 4,666 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $4.48, for a total value of $20,903.68. Following the completion of the sale, the chief operating officer directly owned 137,482 shares in the company, valued at approximately $615,919.36. The trade was a 3.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jose Manuel Otero also recently made the following trade(s):

On Monday, May 18th, Jose Manuel Otero sold 1,302 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $5.07, for a total value of $6,601.14.

Lexeo Therapeutics Trading Down 4.5%

Shares of Lexeo Therapeutics stock opened at $4.45 on Thursday. Lexeo Therapeutics, Inc. has a 12 month low of $3.60 and a 12 month high of $10.99. The firm has a market capitalization of $349.41 million, a P/E ratio of -3.07 and a beta of 1.42. The business has a fifty day simple moving average of $5.12 and a two-hundred day simple moving average of $6.63.

Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.04. Analysts predict that Lexeo Therapeutics, Inc. will post -1.21 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Allworth Financial LP grew its holdings in shares of Lexeo Therapeutics by 1,002.9% during the fourth quarter. Allworth Financial LP now owns 3,386 shares of the company’s stock valued at $34,000 after buying an additional 3,079 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Lexeo Therapeutics by 69.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock worth $35,000 after acquiring an additional 1,459 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Lexeo Therapeutics in the 4th quarter valued at approximately $37,000. California State Teachers Retirement System lifted its position in Lexeo Therapeutics by 123.7% in the 4th quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock valued at $39,000 after acquiring an additional 2,148 shares in the last quarter. Finally, Cerity Partners LLC purchased a new stake in Lexeo Therapeutics during the 2nd quarter valued at $50,000. Institutional investors own 60.67% of the company’s stock.

Analyst Upgrades and Downgrades

LXEO has been the subject of several recent research reports. Wall Street Zen upgraded shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings lowered Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 25th. JPMorgan Chase & Co. dropped their target price on Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating on the stock in a report on Thursday, June 25th. Finally, Chardan Capital reissued a “buy” rating and issued a $17.00 target price on shares of Lexeo Therapeutics in a research note on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $18.75.

Get Our Latest Research Report on LXEO

About Lexeo Therapeutics

(Get Free Report)

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.